Explore more
Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...
This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...
CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...
Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...
Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...
“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...
GlobalData on MSN3d
Eli Lilly’s lepodisiran cuts lipoprotein(a) by 93.9% in Phase II trialThe Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.
Strokes caused by an artery tear are landing five times as many Americans in the hospital these days, a new study says.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback